First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
June 22, 2021 19:22 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia, June 22, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) today announces that a first patient has been dosed in a Phase I study of...
Theralase® Launches Seventh US-Based Clinical Study Site and Treats First Patient in the US
June 11, 2021 07:00 ET
|
Theralase Technologies Inc.
TORONTO, June 11, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
Theralase Releases Q12021 Interim Financial Statements
May 28, 2021 18:58 ET
|
Theralase Technologies Inc.
TORONTO, May 28, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research...
IMAGIN MEDICAL REPORTS MANUFACTURING PROGESS
March 16, 2021 08:05 ET
|
Imagin Medical Inc.
VANCOUVER, B.C. / BOSTON, March 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”)...
IMAGIN MEDICAL CLOSES SECOND TRANCHE OF CONVERTIBLE NOTE OFFERING
February 18, 2021 08:30 ET
|
Imagin Medical Inc.
Vancouver, B.C. and Boston, MA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD3) (“Imagin” or the...
Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years
January 27, 2021 20:30 ET
|
DelveInsight Business Research LLP
Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...
Imagin Medical Engages Torrey Hills Capital
January 20, 2021 08:30 ET
|
Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (FSE: DPD2) ("Imagin" or the "Company") is pleased to...
Imagin Medical Builds Momentum for 2021
January 13, 2021 08:30 ET
|
Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical (CSE: IME) (OTC: IMEXF) (FRA: DPD2) (the “Company”) announces that critical milestones...
InvestorBrandNetwork (IBN) Coverage Initiated for Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF)
January 13, 2021 08:30 ET
|
InvestorBrandNetwork (IBN)
NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing...
New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting
December 02, 2020 10:03 ET
|
FerGene Inc.
CAMBRIDGE, Mass, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Low rate of cystectomy and delayed time to cystectomy among patients who achieved complete responsePatient characteristics or prior treatment...